Generated by AI
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on precision genetic medicines for rare diseases, with a strong emphasis on rare neuromuscular disorders. The company develops RNA-targeted therapeutics, siRNA-based treatments, gene therapies, and other genetic medicine modalities designed to address underlying disease mechanisms. Its current portfolio includes approved and commercialized therapies for Duchenne muscular dystrophy, along with additional programs in development for other rare genetic conditions. Sarepta Therapeutics also maintains a broader research and manufacturing platform centered on advancing genetic medicine from discovery through delivery. Based in Cambridge, Massachusetts, the company plays a notable role in the rare disease market by combining therapeutic innovation with a specialized focus on patients who often have limited treatment options.
Website215 First Street
Cambridge, MA, 02142
United States
The latest articles about SRPT.
Sarepta Therapeutics reported Q3 2026 revenue of US$381.35 million with a narrower net loss, and later raised the low end of its 2026 total net product revenue guidance by US$50 million to a range of US$1.25 billion to US$1.3 billion. The higher outlook leans on a stabilizing ELEVIDYS gene therapy business and a resilient PMO franchise, even as year-to-date revenue trails the prior period and Q3 earnings fell short of analyst expectations. This article examines how Sarepta Therapeutics'...
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of May 6's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about SRPT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.